Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 5/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 5/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30811828 | 1.00 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL1502674 | 0.78 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL1559218 | 0.78 | CYP3A4 (0.52) | CHRNB2CHRNA4ALOX15MAPTCYP2A6 | |
| SCHEMBL5659919 | 0.74 | CHRNB2 (0.47) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL30201408 | 0.74 | MAPT (0.52) | POLBMAPTCYP2A6KDM4EMEN1 | |
| SCHEMBL16720482 | 0.74 | CHRNB2 (0.42) | CHRNB2CHRNA4POLBMAPTCYP2A6 | |
| SCHEMBL3931376 | 0.74 | MAPT (0.52) | POLBMAPTCYP2A6KDM4EMEN1 | |
| SCHEMBL12369610 | 0.74 | CHRNB2 (0.44) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL14909303 | 0.74 | HTT (0.40) | CHRNB2CHRNA4CHRNB4CHRNA3POLB | |
| SCHEMBL30811728 | 0.72 | CHRNB2 (0.56) | CHRNB2CHRNA4CHRNB4CHRNA3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4582422-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | Global Health Drug Discovery Institute (CN) | 2025-07-09 | — | — | EP | disclosed |
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | GLOBAL HEALTH DRUG DISCOVERY INSTITUTE (CN) | 2025-07-03 | — | — | US | disclosed |
| CN-117736182-A | MetTL3 inhibitors and uses thereof | 成都先导药物开发股份有限公司 | 2024-03-22 | — | — | CN | disclosed |
| WO-2024056099-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 北京华益健康药物研究中心 | 2024-03-21 | — | — | WO | disclosed |
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | RAQUALIA PHARMA INC. (JP) | 2023-10-31 | — | — | US | disclosed |
| WO-2023104209-A1 | METTL3 INHIBITOR COMPOUND | 上海昂阔医药有限公司 | 2023-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11802120-B2 | Fused cyclic urea derivatives as CRHR2 antagonist | CRHR2, CRHR1, CRH | CHRNB2 1703/4885CHRNA4 2400/4885CHRNB4 2651/4885 |
| US-20250214997-A1 | METTL3 INHIBITOR COMPOUND, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | METTL3, METTL14, METTL16 | CHRNB2 4468/4885CHRNA4 4400/4885CHRNB4 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.